Exact Sciences has acquired Ashion Analytics to help accelerate the development of its precision oncology portfolio, including minimal residual disease (MRD) and other sequencing-based tests, the company announced recently.
According to a release, Ashion leverages the genetic information from a patient’s tumor and normal genomes to provides industry-leading oncology solutions. The Ashion team will help incorporate the TARDIS technology into Exact Sciences’ MRD test development.
The biotech company also announced its 10-year collaboration with TGen and City of Hope to develop differentiated MRD testing capabilities for patients and establish the clinical evidence necessary to drive adoption.
“We’re excited to work with Ashion to bring the TARDIS technology to patients faster and continue to develop advancements in MRD testing,” Exact Sciences CEO Kevin Conroy said in a statement. “We’re thrilled to collaborate with TGen and City of Hope, complementing our relationships with other world-renowned cancer research leaders including Mayo Clinic and Johns Hopkins University.”
Financial terms were not disclosed.